

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

August 20th, 2024

To The Manager, Listing Departments, BSE Limited, P. J. Towers, Da1a1 Street, Mumbai – 400 001. Scrip Code: 524212	To, The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, C - 1, Block- G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Symbol: WANBURY
--	--

Dear Sir/Madam,

Sub.: Press release on Q1FY25 Financial Results

Please find attached herewith copy of press release on Q1FY25 Financial Results.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd

Jitendra J. Gandhi
Company Secretary

Encl.: a/a.





Wanbury Ltd Reports Q1FY25 Results

20th August, 2024, MUMBAI: Wanbury Ltd, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter ended June 30, 2024.

Consolidated Q1FY25 Financial Highlights

(Rs in Crore)

Particulars	Q1 FY25	Q1 FY24	Q4 FY24
Revenue from Operations	131.1	146.3	139.4
EBITDA	11.9	14.0	19.1
EBITDA Margin (%)	9.1%	9.5%	13.7%
PAT	1.0	4.7	8.1
PAT Margin (%)	0.8%	3.2%	5.8%

Key Highlights

- Successful clearance of the USFDA inspection of the Patalganga site for the 6th time, concluded on June 14, 2024, with zero-483 observations.
- The manufacturing facility at Patalganga was undergoing upgradation and renovation for part of the current quarter, and thus it was not utilized to its optimum levels, which impacted revenues and profitability for the quarter.
- To lead the company's strategic direction and drive growth, Mr. V. Prakash has been appointed as the Head of API business.

Commenting on the performance, **Mr. Mohan Rayana, Director of Wanbury Ltd.**, said, "We are delighted to inform you that our Patalganga manufacturing facility has again successfully cleared the USFDA inspection with zero-483 observations. This demonstrates our strong focus on quality products and good manufacturing practices.

The budgeted sales & profitability in the coming quarters will be restored due to full production in both plants at Patalganga & Tanuku, besides cost reduction & improvement in solvent recoveries."





About Wanbury Ltd.

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact

Jitendra J. Gandhi
Company Secretary,
Wanbury Limited
BSEL Techpark, B' Wing, 10th Floor,
Sector 30-A, Opp. Vashi Railway Station,
Vashi, Navi Mumbai - 400703, India.
Tel: +91-22-6794 2222
Email: jitendra.gandhi@wanbury.com

Hanishi Shah / Anand Venugopal
Adfactors PR
Oasis Complex, Kamala Mills Compound, City Hall,
Pandurang Budhkar Marg, Lower Parel West,
Mumbai – 400021
Tel: +91 9619059339 / +91 7021852071
Email: hanishi.shah@adfactorspr.com
anand.venugopal@adfactorspr.com

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

